esomeprazole + placebo

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Vasomotor Rhinitis

Conditions

Vasomotor Rhinitis

Trial Timeline

Jun 1, 2005 → Mar 1, 2008

NCT ID

NCT00745849

About esomeprazole + placebo

esomeprazole + placebo is a pre-clinical stage product being developed by AstraZeneca for Vasomotor Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00745849. Target conditions include Vasomotor Rhinitis.

What happened to similar drugs?

1 of 14 similar drugs in Vasomotor Rhinitis were approved

Approved (1) Terminated (0) Active (13)

✅17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved

🔄fezolinetant + placeboAstellas PharmaPhase 3

🔄DVS-233 SRPfizerPhase 3

🔄Bazedoxifene/Conjugated EstrogenPfizerPhase 3

🔄desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3

🔄desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3

🔄Elinzanetant (BAY3427080) + PlaceboBayerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01069939	Phase 3	Completed	Feb 1, 2010	Nov 1, 2011	Prevention
NCT00660660	Approved	Completed	Apr 1, 2008	Jul 1, 2008	Gastroesophageal Reflux Disease
NCT00542789	Phase 3	Completed	Aug 1, 2007	Feb 1, 2009	Gastric Ulcer
NCT00287339	Approved	Completed	Sep 1, 2005	Sep 1, 2008	Cough
NCT00745849	Pre-clinical	Completed	Jun 1, 2005	Mar 1, 2008	Vasomotor Rhinitis
NCT00628953	Phase 2	Completed	Oct 1, 2002	Apr 1, 2004	Asthma
NCT00628667	Approved	Completed	Feb 1, 2002	Mar 1, 2003	Chronic Posterior Laryngitis (CPL)

Competing Products

20 competing products in Vasomotor Rhinitis

See all competitors

Product	Company	Stage	Hype Score
fezolinetant + placebo	Astellas Pharma	Phase 3	40
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiol	Eli Lilly	Phase 2	35
MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mg	Merck	Phase 2	27
Erenumab + Placebo	Amgen	Phase 1	29
17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)	Pfizer	Approved	43
DVS-233 SR	Pfizer	Phase 3	40
Bazedoxifene/Conjugated Estrogen	Pfizer	Phase 3	40
desvenlafaxine succinate sustained release (DVS SR)	Pfizer	Phase 1	29
desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release	Pfizer	Phase 3	40
desvenlafaxine succinate (DVS) SR + Placebo	Pfizer	Phase 3	40
Treatment A + Treatment B + Treatment C	Bayer	Phase 1	26
Elinzanetant (BAY3427080) + Placebo	Bayer	Phase 1	26
Elinzanetant (BAY3427080) + Placebo	Bayer	Phase 3	41
Elinzanetant (BAY3427080) treatment A + Elinzanetant (BAY3427080) treatment B	Bayer	Phase 1	26
Elinzanetant (BAY3427080)	Bayer	Phase 1	26
Moxifloxacin + Elinzanetant (BAY3427080) + Placebo	Bayer	Phase 1	26
Elinzanetant (BAY3427080) + Dabigatran etexilate	Bayer	Phase 1	26
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg	Bayer	Phase 3	37
BAY3427080	Bayer	Phase 1	26
Elinzanetant (BAY3427080) + Rosuvastatin	Bayer	Phase 1	26